Market capitalization | $197.54m |
Enterprise Value | $202.88m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-8.45m |
Free Cash Flow (TTM) Free Cash Flow | $-7.20m |
Cash position | $4.91m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Kintara Therapeutics Inc:
1 Analyst has issued a forecast Kintara Therapeutics Inc:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.06 -0.06 |
0%
0%
|
|
EBITDA | -8.40 -8.40 |
43%
43%
|
EBIT (Operating Income) EBIT | -8.45 -8.45 |
43%
43%
|
Net Profit | -8.32 -8.32 |
43%
43%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Head office | United States |
CEO | James Bianco |
Employees | 11 |
Founded | 2009 |
Website | www.tuhurabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.